🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06774703
Starting soon Observational

Nemaline Myopathy Clinical Research Network (NM-CTRN)

NCT06774703 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2025-01
Last updated
2025-01-14

Condition(s) studied

Nemaline Myopathy

Study summary

The goal of this study is to establish a research network to help define the natural disease history and clinical outcome measures for Nemaline Myopathy (NM).

Eligibility

Sex
ALL
Min age
0 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * 0-18 years of age at recruitment * Confirmation of Nemaline Myopathy (pathogenic or likely pathogenic mutations in ACTA1 (AD) or NEB (AR) * Patient and/or parent or legal guardian must be willing and able to provide informed consent Exclusion Criteria: * Clinically significant medical finding on the physical examination, other than NM, that the Investigator deems unsuitable for participation in and/or completion of the study procedures * Any confirmed chronic or acute condition or disease affecting any system(s), which could interfere with the results of the study and/or the compliance with the study procedures. This will be subject to the clinical judgement of the Principal Investigator (PI) * Participants of ongoing (interventional) clinical trials that assess the efficacy of potential treatments will be excluded * Safety concerns

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Stanford University/Lucile Packard Children's Hospital Palo Alto California
National Institute of Health Bethesda Maryland
Boston Children's Hospital Boston Massachusetts
St Jude Children's Research Hospital Memphis Tennessee
UT Southwestern Medical Centre/Children's Health Dallas Dallas Texas
The Hospital for Sick Children Toronto Ontario

More Stanford University trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06774703 on ClinicalTrials.gov ↗ ← All trials in Canada